Literature DB >> 2311339

Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum.

B Lecocq1, C Funck-Brentano, V Lecocq, A Ferry, M E Gardin, M Devissaguet, P Jaillon.   

Abstract

Food has been shown to reduce the bioavailability of the angiotensin-converting enzyme inhibitor captopril, but not the bioavailability of inhibitors administered as ester prodrugs. Perindopril is the ester pro-drug of the angiotensin-converting enzyme inhibitor perindoprilat. The influence of food on the pharmacokinetics of perindopril (4 mg administered orally) and the time course of angiotensin-converting enzyme inhibition in serum was studied in a randomized crossover short-term study of 12 healthy subjects. Food significantly decreased the relative availability of perindoprilat by 35% +/- 42%, the fractional urinary excretion of perindoprilat from 19% +/- 7% to 13% +/- 4% (p less than 0.05), and the partial metabolic clearance of perindopril to perindoprilat from 102 +/- 57 ml.min-1 to 72 +/- 32 ml.min-1 (p less than 0.05). These changes were associated with a significant decrease in the area under the percent angiotensin-converting enzyme inhibition-versus-time curve by 15% (p less than 0.05). Food did not alter the total amount of drug recovered in urine as perindopril and its metabolites, and it did not alter perindoprilat renal clearance. We concluded that food alters the conversion of perindopril to its active metabolite perindoprilat after single-dose administration of perindopril.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311339     DOI: 10.1038/clpt.1990.45

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  The pharmacokinetics of perindopril in patients with liver cirrhosis.

Authors:  M Thiollet; C Funck-Brentano; J D Grangé; M Midavaine; G Resplandy; P Jaillon
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

4.  Effects of Chungsinoryungsan, a polyherbal complex, on the pharmacokinetic profiles of perindopril in rats.

Authors:  Seok-Bong Kang; Ho-Sang Shon; Soo-Jin Park; Chang-Hyun Song; Sae-Kwang Ku
Journal:  Biomed Rep       Date:  2014-08-05

Review 5.  Perindopril: an updated review of its use in hypertension.

Authors:  M Hurst; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of the newer ACE inhibitors. A review.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

7.  Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers.

Authors:  P J Anderson; J A Critchley; B Tomlinson; G Resplandy
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

Review 8.  Influence of diet and nutritional status on drug metabolism.

Authors:  I Walter-Sack; U Klotz
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 9.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

Review 10.  Pharmacokinetic changes in patients with oedema.

Authors:  B Vrhovac; N Sarapa; I Bakran; M Huic; V Macolic-Sarinic; I Francetic; A Wolf-Coporda; F Plavsic
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.